MTD

Mettler ToledoNYSE · Life Sciences Tools & Services · Health Care

Previous close

1,674.81

Change

−43.80 / −2.55%

FinDog View

Bullish

52-Week Range ?

1,023.05 – 1,728.66

P/E (TTM) ?

37.2

Forward P/E ?

35.6

Based on consensus earnings for the next 12 months

Market Cap

$33.8B

+10.84%

S&P 500 −0.91% over same period

Volume / Avg Volume

190K / 170K

1.12× average

Latest earnings analysisFY2026 Q2Reported 2026-07-30

Mettler-Toledo Q2 2026: sales up 4%, EPS $11.55, guidance raised

Mettler-Toledo beat on both lines in Q2 2026: adjusted EPS was $11.46 against a $10.90 consensus, and full-year guidance moved up. Read the quarter carefully — a one-time $52 million US tariff refund flattered cost of sales, and gross margin's jump from 59.0% to 63.3% is mostly that. Organic local currency sales grew 4%, with the Americas the weak spot.

Read the full analysis →

Revenue$1.03BYoY +4.50%

EPS (non-GAAP)$11.46Beatest. $10.90

Next-day move+2.59%

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 32.11M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q2 Quarter ended 2026-06	2026-07-30	$1.0B	11.46 / 10.90	+2.59%	Read analysis →
FY2026 Q1 Quarter ended 2026-03	2026-05-07	$947M	8.91 / 8.79	−14.77%	Pending
FY2025 Q4 Quarter ended 2025-12	2026-02-05	$4.0B	13.36 / 12.93	−0.67%	Pending
FY2025 Q3 Quarter ended 2025-09	2025-11-06	$1.0B	11.15 / 10.74	−0.02%	Pending
FY2025 Q2 Quarter ended 2025-06	2025-08-01	$983M	10.09 / —	+2.89%	Pending
FY2025 Q1 Quarter ended 2025-03	2025-05-01	$884M	8.19 / —	+4.11%	Pending

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →

Report date

2026-11-05

in 4 days · After hours

Consensus EPS

$12.22

Last quarter EPS $11.46

Avg. next-day move over the last 6 reports

±4.2%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 84 of its 5-year rangeExpensive

5-year range 26.1 – 40.0 · Median 32.5

Last 4 quarters: $775M in buybacks + $0 in dividends, 2.30% of market cap combined

P/E (TTM)

37.2

P/B

—

P/S

8.1

PEG

3.05

Earnings Reaction

Over the last 6 reports, the stock moved ±4.2% on average on the first trading day after, rising 3 times

Most recent +2.59%

Volatility & Correlation

1-year beta 0.81 · Correlation with S&P 500 0.33Tracks the market

Annualized volatility 31% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 5 · $6.1MNet selling $6.1M

08-27Kaltenbach PatrickPresident and CEOSell$1.3M942 shares · Avg price 1,425.00
08-05SALICE THOMAS PDirectorSell$0.60M417 shares · Avg price 1,440.41
08-03Vadala ShawnChief Financial OfficerSell$3.2M2,240 shares · Avg price 1,432.00
08-03Keller GerryHead of Process AnalyticsSell$0.34M240 shares · Avg price 1,427.14
08-03SALICE THOMAS PDirectorSell$0.60M415 shares · Avg price 1,444.62

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q2	1.03	+4.5%	—	—	0.23	0.28	11.55
FY2026 Q1	0.95	+7.2%	—	—	0.17	0.12	8.33
FY2025 Q4	1.13	+8.1%	—	—	0.29	0.18	13.91
FY2025 Q3	1.03	+7.9%	—	—	0.22	0.27	10.57
FY2025 Q2	0.98	+3.9%	—	—	0.20	0.21	9.76
FY2025 Q1	0.88	−4.6%	—	—	0.16	0.18	7.81
FY2024 Q4	1.05	+11.8%	—	—	0.25	0.22	11.91
FY2024 Q3	0.95	+1.3%	—	—	0.21	0.23	9.96
FY2024 Q2	0.95	−3.6%	—	—	0.22	0.23	10.37
FY2024 Q1	0.93	−0.3%	—	—	0.18	0.17	8.24
FY2023 Q4	0.93	−11.6%	—	—	0.18	0.25	8.53
FY2023 Q3	0.94	−4.4%	—	—	0.20	0.24	9.21

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
MTD	Mettler Toledo	$33.8B	37.2	+4.5%	—	+10.84%	Bullish
LLY	Lilly (Eli)	$1.34T	50.2	+38.6%	83.9%	+22.51%	Bullish	Compare
JNJ	Johnson & Johnson	$666B	41.3	+5.9%	68.1%	+3.20%	Bullish	Compare
ABBV	AbbVie	$522B	81.4	+10.2%	74.7%	+12.73%	Bullish	Compare
UNH	UnitedHealth Group	$367B	23.0	+0.4%	88.1%	+10.87%	Bullish	Compare
MRK	Merck & Co.	$371B	117.2	+5.1%	73.5%	+2.90%	Neutral	Compare
TMO	Thermo Fisher Scientific	$258B	36.4	+9.1%	—	+3.25%	Neutral	Compare
AMGN	Amgen	$254B	28.5	+9.5%	72.0%	+10.56%	Bullish	Compare
GILD	Gilead Sciences	$213B	—	+6.8%	81.1%	+14.51%	Neutral	Compare

The View in One Line

Revenue $1.03B +4.5%, adjusted EPS $11.46 beat, organic growth recovering, FY guidance raised; bullish; Americas +1% and high debt to watch.

Updated 2026-10-30

View History

09-17Neutral → Bullish
Adjusted EPS beat, organic growth recovering, guidance raised, bullish; watch weak Americas and high debt.

ETFs holding it

XLV Health Care Select Sector SPDR Fund0.50%
RSP Invesco S&P 500 Equal Weight ETF0.28%
SCHG Schwab U.S. Large-Cap Growth ETF0.14%
VUG Vanguard Growth ETF0.12%
IVV iShares Core S&P 500 ETF0.05%
VOO Vanguard S&P 500 ETF0.05%
SPY SPDR S&P 500 ETF Trust0.05%
VTI Vanguard Total Stock Market ETF0.05%

Weights estimated at latest prices

Key Events

08-03Management Change
Mettler-Toledo Appoints Natalia Shuman to Board
On July 30, 2026, the board appointed Natalia Shuman as an independent director effective August 3, expanding the board from nine to ten members.Source ↗
05-13Management Change
Mettler-Toledo Grants 2026 Long-Term Incentives to Executives
On May 7, the Compensation Committee approved 2026 long-term incentives, granted in two tranches in May and November, with the CEO's target value up about 6.25% versus 2025.Source ↗
05-11Governance
Mettler-Toledo Annual Meeting Voting Results Announced
At the May 7, 2026 annual meeting, 9 directors were elected, PricewaterhouseCoopers was ratified as auditor, and an advisory executive compensation vote passed.Source ↗

Key Financial Trends

Quarterly Revenue ($B)1.0

Free Cash Flow ($B)0.3